Genome and Company
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 17, 2027The maintenance fee for Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient (US 11,787,870) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 10 US 12,790,393 ANTI-CNTN4-SPECIFIC Antibodies and Use Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,571,448 | Lactobacillus rhamnosus LM1019 strain and composition for preventing and treating obesity or diabetes mellitus comprising same In force · USPTO record | In force | USPTO record | |
| US 11,406,589 | Cutibacterium granulosum strain, and composition comprising such strain or culture thereof for preventing or treating acne In force · USPTO record | In force | USPTO record | |
| US 11,478,513 | Cutibacterium avidum strain, and composition for preventing or treating atopic dermatitis, comprising strain or cultured product thereof In force · USPTO record | In force | USPTO record | |
| US 11,453,857 | Lactobacillus fermentum LM1016 strain (KCCM12468P) In force · USPTO record | In force | USPTO record | |
| US 11,787,870 | Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient In force · USPTO record | In force | USPTO record | |
| US 12,214,004 | Strains having effects of preventing or treating cancers In force · USPTO record | In force | USPTO record | |
| US 12,790,393 | ANTI-CNTN4-SPECIFIC Antibodies and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,600,765 | Novel Target for Anti-Cancer and Immune-Enhancing In force · Low confidence | In force | Low confidence | |
| US 12,564,613 | Novel Strains Having Effects of Preventing or Treating Cancers In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 3 abandoned · 8 no status recorded